DTIL Precision BioSciences Company Cash Volume

Graphic logo of Precision BioSciences Inc. (DTIL)

Precision BioSciences owns the unique ARCUS system, which provides exceptional pricing power due to the precision of its genome editing. These advantages translate into future licensing and therapy revenues, as clearly demonstrated by the cash balance. The value of 0.08 characterizes this liquidity assessment parameter. The process is being accelerated by the implementation of robotic stations for automated molecular screening.

DTIL - precisionbiosciences.com Company Liquid Assets over the range 07/04/2022 - 11/21/2026

Precision BioSciences, Inc. (DTIL) - metric breakdowns and financial figures

- stock value and consensus price forecast:
Fundamental company analysis:precisionbiosciences.com
Signature product of precisionbiosciences.com

Given the exceptional value of the ARCUS platform and the inelastic demand for its technologies, the free cash flow of Precision BioSciences (DTIL) serves as an indicator of financial autonomy during the development of intellectual property. This metric aggregates cash and cash equivalents, allowing for an assessment of the balance between protection against market volatility and the efficiency of reinvesting capital into business expansion.

Competitors of Precision BioSciences (DTIL)

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Volume EDIT (Editas Medicine Inc)|SLN: Company Cash and Cash Equivalents|PRQR - Company Cash Funds|Company Liquid Assets codexis.com CDXS|SGMO: Company Cash Volume|Nautilus Biotechnology (NAUT) - Company Cash Volume|Company Cash Funds Metagenomi, Inc|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume